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We reported molecular cloning of B cell
stimulatory factor-2 (BSF-2)/interleukin 6
(IL-6) in 1986 (1), the same year that IL-4
and IL-5 were cloned (2, 3). Prior to the
publication of our article (1), it was known
that antigenic stimulation induced growth
and differentiation of B lymphocytes into
antibody forming plasma cells with the
help of T lymphocytes and this function of
T lymphocytes could be replaced by soluble
factors. Dutton in 1971 and Schimpl and
Wecker in 1972 reported the presence of
soluble factors that induced immunoglob-
ulin production in B lymphocytes in the
absence of T lymphocytes (4, 5). Schimpl
and Wecker named the putative factor “T
cell replacing factor” (TRF). In addition,
Kishimoto and Ishizaka reported a solu-
ble factor that enhanced IgE antibody pro-
duction (6), while Takatsu and his col-
leagues reported a factor that enhanced
anti-hapten antibody production (7). The
molecular characteristics of these soluble
factors, however, were unknown. Further-
more, other reports showed the possibil-
ity that there might be several kinds of
soluble factors that affected the biologi-
cal activities of B lymphocytes differently
(8, 9). For example, Paul and his col-
leagues showed that the culture super-
natant of mouse thymoma EL4 in com-
bination with submitogenic doses of anti-
IgM antibodies stimulated the prolifer-
ation of B lymphocytes without induc-
ing antibody production (10). The puta-
tive factor was called “BCGF-I” or “BSF-
1.” Swain and Dutton showed that cul-
ture supernatants from a long-term allore-
active T cell line, DL, induced growth
in dextran sulfate stimulated B lympho-
cytes and BCL1 B cell tumors. The same
culture supernatant when combined with
IL-2 induced another response: antibody
production in B cells (11). This putative
factor was called “BCGF-II.” Thus, prior
to our article, little was known about the
molecular nature of the factors responsible
for B lymphocyte stimulation, which is why
many immunologists reported each factor
by a different name based on its biological
activity.
After studying at A. Nordin’s lab in
the United States National Institutes of
Health from 1973 to 1976, I returned
to Y. Yamamura’s lab at Osaka Univer-
sity Medical School, where we showed that
PWM-stimulated human T lymphocytes
produced soluble factor(s) that induced
immunoglobulin production in human
B lymphocytes (12). In 1978, I moved
to Osaka Prefectural Habikino Hospital
where I saw many patients with tuber-
culous pleurisy. What I found there was
that purified protein derivative (PPD)-
stimulated pleural effusion cells from these
patients produced soluble factor(s) that
induced immunoglobulin production in
PWM-stimulated human B lymphocytes
(13). This finding led me to start purify-
ing the putative factor in 1978. In 1981,
Kishimoto’s group showed the presence of
a soluble factor that enhanced IgG pro-
duction in an Epstein–Barr virus trans-
formed human B cell line, CESS. This
putative factor was named “TRF” (14).
We showed that the culture supernatant
of PPD-stimulated pleural effusion cells
obtained from patients with pulmonary
tuberculosis or PWM-stimulated tonsillar
mononuclear cells induced IgG produc-
tion in a variety of Epstein–Barr virus-
transformed B lymphoblastoid cell lines
(15), which we called a “TRF-like factor” or
“B cell differentiation factor II” (BCDFII)
(15–17). We showed that the TRF-like fac-
tor/BCDFII was recovered in the fractions
corresponding to the molecular weights 22
and 36 kDa by gel filtration, and that it had
an isoelectric point between 5 and 6 (15).
In early 1984, I joined Kishimoto’s lab
as an Associate Professor at Osaka Uni-
versity and continued purifying the puta-
tive factor from the culture supernatant of
the HTLV-transformed human T cell line,
TCL-NA1. We soon thereafter determined
the sequence of its 14 N-terminal amino
acids with the help of S. Tsunasawa, Insti-
tute for Protein Research, Osaka University
at the end of 1984. The purified material
had molecular weights of 19 and 21 kDa
as identified by NaDodSO4/PAGE under
reduced as well as non-reduced conditions.
The IgG-inducing activity was found in
the fractions corresponding to the molecu-
lar weights noted above and the isoelectric
point ranged from 5.0 to 5.1 (18). We con-
cluded that this material, which we called
“BCDF” or “BSFp-2,” had properties what
were similar to those of the TRF-like fac-
tor/BCDFII (15). Importantly, the purified
protein did not exhibit any of the activities
of IL-1 or -2, BCGF-I/BSF-1, BCGF-II or
interferon (18).
Then we started the molecular cloning
of the purified protein, using a probe based
on information about the N-terminal par-
tial amino-acid sequence with the kind help
of T. Taniguchi, Osaka University. How-
ever, this procedure was much harder than I
expected. Because of the many false positive
clones bound to the probe, we were unable
to obtain the cDNA encoding of the mole-
cule with the identified N-terminal amino-
acid sequence in 1985. This caused us great
consternation, and we worried whether the
identified sequence was correct. During
this period, I suffered severe arrhythmia,
which I attribute to the stress of the project.
At the very beginning of 1986, I decided
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to purify the protein using newly obtained
culture supernatants from TCL-NA1 cells.
This time, instead of obtaining the N-
terminal partial amino-acid sequence of
the purified protein, I decided to acquire
several fragments of the purified protein
by digesting the protein with lysylendopep-
tidase, following the thoughtful advice of
S. Tsunasawa. There was a serious risk of
losing all the purified protein, however,
due to the additional process of separating
the fragmented peptides with high perfor-
mance liquid chromatography. Nonethe-
less, our previous failures convinced me, we
had little choice. On February 20 of that
year, Honjo and his colleagues reported
the molecular cloning of murine IgG1
induction factor, or IL-4 (2). However, I
remained firm in the need to isolate the
cDNA encoding of our purified protein.
We were lucky to have obtained several
protein fragments during the additional
purification step, which eventually led us to
successfully obtain their partial amino-acid
sequences by the end of March 1986. We
selected three highly reliable N-terminal
partial amino-acid sequences from among
eight fragments to make synthetic oligonu-
cleotide probes, which we then used to
clone the cDNA. On Sunday morning of
May 25, 1986, I finally found one cDNA
clone out of about 30,000 that miracu-
lously – at least in my opinion – was bound
by all three probes. Thus, after 8 years
of hard work, beginning in 1978 when I
started the purification of helper T cell fac-
tors at Osaka Prefectural Habikino Hospi-
tal, I had finally obtained the cDNA encod-
ing of the protein inducing immunoglob-
ulin in B cells, which we called “BSF-2” at
that time. From the cDNA sequence, we
predicted that the mature form of BSF-2
is composed of 184 amino acids and has
an isoelectric point of 5, again, very sim-
ilar to the TRF-like factor/BCDFII (15).
This result was published in a November
issue of Nature in 1986 (1) together with
a report on the molecular cloning of IL-5
(3). The sequence of BSF-2 was found to be
identical to that of an IL-1-induced 26-kDa
protein with unknown biological activity,
which was reported in the September issue
of the European Journal of Biochemistry
(19) and the sequence of IFN-β2,which was
reported in the October issue of the EMBO
Journal (20). In addition, the plasmacy-
toma/hybridoma/myeloma growth factor
and the hepatocyte-stimulating factor were
found to be identical to BSF-2 (21–25).
At a nomenclature meeting in New York
chaired by W. E. Paul at the end of 1988,
the community agreed to call this molecule
“IL-6” (26).
Our project originally began with the
desire to isolate a factor responsible
for stimulating B lymphocytes to pro-
duce immunoglobulin. What we found
was something far more complex. IL-6
is a multifunctional cytokine that plays
roles in immune responses, inflamma-
tion, hematopoiesis, and the endocrine and
nervous systems, even though it has no
interferon activity (27–29). Additionally,
we revealed that IL-6 might be involved
in autoimmune diseases and inflamma-
tory diseases (30–33), opening the way for
new therapies that regulate inflammatory
diseases (34–37).
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